Nathalie Van Den Berghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathalie Van Den Berghe has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Bram Verstockt
Department of Gastroenterology and Hepatology University Hospitals Leuven KU Leuven Leuven Belgium
6 shared publications - Debby Thomas
Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
4 shared publications - Severine Vermeire
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
4 shared publications - Ann Gils
Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
3 shared publications - Marc Ferrante
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
3 shared publications Ann Gils
Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- 1 March 2023
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 21 (3) , 838-840.e2
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s Disease
- 1 March 2023
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 21 (3) , 838-840.e2
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s Disease
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S338-S339
P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
Various studies have shown an association between ustekinumab serum concentrations and treatment response in patients with Crohn’s disease (CD). However, the time point at which this concentration is most informative for long-term outcome is unknown. Dried blood spot (DBS) sampling allows remote collection of blood for measurements at various time points. By use of this sampling method, the current study aimed to evaluate the exposure-response relationship of ustekinumab throughout the first 24 weeks of treatment and to investigate the time points at which ustekinumab levels could identify patients achieving endoscopic remission. This interim-analysis included DBS (n = 332) and serum (n = 60) samples collected from 13 ustekinumab-treated CD patients at 25 time points during the first 6 months of therapy. All patients received an intravenous infusion of ~6 mg/kg ustekinumab followed by subcutaneous dosing of 90 mg every 8 weeks. Ustekinumab concentrations were measured in serum and DBS extracts using an ustekinumab ELISA (apDia, Turnhout, Belgium). Endoscopic remission was defined as simple endoscopic score for CD (SES-CD) ≤3 after 6 months of therapy. The Mann-Whitney U-test was used to compare unpaired data. Three out of 13 patients (23.1%) achieved endoscopic remission. Ustekinumab concentrations in serum correlated with those in DBS extracts (Spearman r = 0.97, p <0.0001). Measurement of the ustekinumab concentration in 38 simultaneously collected DBS and serum samples showed an average DBS-to-serum conversion factor of 2.5±0.7 (mean±SD) with an acceptable interpatient variability (CV ≤29%). Concentration-time profiles showed that patients in remission have a higher area under the curve (AUC), hence a higher drug exposure, than patients not achieving remission (906 vs 466 μg*day/mL, p=0.007, Figure). A negative correlation was observed between the AUC and SES-CD at week 24 (Spearman r = -0.74, p=0.0048). Ustekinumab concentrations in DBS extracts at the intermediate time points week 6, week 11 and week 12 after treatment start exhibited the most significant difference between remitters and non-remitters (Table). In contrast, no significant difference was observed in ustekinumab levels in DBS extracts at week 8, week 16 and week 24 between remitters and non-remitters. Intensive DBS sampling showed that ustekinumab-treated CD patients in endoscopic remission have a higher drug exposure throughout the first 24 weeks of treatment than patients not in remission. DBS is an easy sampling method that allows accurate monitoring of ustekinumab exposure over time and could help to identify underexposed patients which might benefit from treatment optimization.
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S338-S339
Open AccessP311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
Various studies have shown an association between ustekinumab serum concentrations and treatment response in patients with Crohn’s disease (CD). However, the time point at which this concentration is most informative for long-term outcome is unknown. Dried blood spot (DBS) sampling allows remote collection of blood for measurements at various time points. By use of this sampling method, the current study aimed to evaluate the exposure-response relationship of ustekinumab throughout the first 24 weeks of treatment and to investigate the time points at which ustekinumab levels could identify patients achieving endoscopic remission. This interim-analysis included DBS (n = 332) and serum (n = 60) samples collected from 13 ustekinumab-treated CD patients at 25 time points during the first 6 months of therapy. All patients received an intravenous infusion of ~6 mg/kg ustekinumab followed by subcutaneous dosing of 90 mg every 8 weeks. Ustekinumab concentrations were measured in serum and DBS extracts using an ustekinumab ELISA (apDia, Turnhout, Belgium). Endoscopic remission was defined as simple endoscopic score for CD (SES-CD) ≤3 after 6 months of therapy. The Mann-Whitney U-test was used to compare unpaired data. Three out of 13 patients (23.1%) achieved endoscopic remission. Ustekinumab concentrations in serum correlated with those in DBS extracts (Spearman r = 0.97, p <0.0001). Measurement of the ustekinumab concentration in 38 simultaneously collected DBS and serum samples showed an average DBS-to-serum conversion factor of 2.5±0.7 (mean±SD) with an acceptable interpatient variability (CV ≤29%). Concentration-time profiles showed that patients in remission have a higher area under the curve (AUC), hence a higher drug exposure, than patients not achieving remission (906 vs 466 μg*day/mL, p=0.007, Figure). A negative correlation was observed between the AUC and SES-CD at week 24 (Spearman r = -0.74, p=0.0048). Ustekinumab concentrations in DBS extracts at the intermediate time points week 6, week 11 and week 12 after treatment start exhibited the most significant difference between remitters and non-remitters (Table). In contrast, no significant difference was observed in ustekinumab levels in DBS extracts at week 8, week 16 and week 24 between remitters and non-remitters. Intensive DBS sampling showed that ustekinumab-treated CD patients in endoscopic remission have a higher drug exposure throughout the first 24 weeks of treatment than patients not in remission. DBS is an easy sampling method that allows accurate monitoring of ustekinumab exposure over time and could help to identify underexposed patients which might benefit from treatment optimization.
- 27 November 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (6) , 988-993
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations
Background and Aims: Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.Methods: A paired serum sample and colonic mucosal biopsy was collected from 40 UC patients [20 endoscopic responders, 20 non-responders] at week 14 of vedolizumab treatment. Vedolizumab, soluble [s]-mucosal addressin cell adhesion molecule-1 [MAdCAM-1], s-vascular cell adhesion molecule-1 [VCAM-1] and s-intercellular adhesion molecule-1 [ICAM-1] were measured in serum and/or tissue. Endoscopic response was defined as Mayo endoscopic sub-score ≤1.Results: A significant positive correlation was observed between vedolizumab serum and colonic tissue concentrations [ρ = 0.84, p < 0.0001], regardless of the macroscopic inflammatory state of the tissue. Vedolizumab tissue concentrations were lower in non-responders than in responders [0.07 vs 0.11 µg/mg, p = 0.04]. In the subgroup of patients with adequate vedolizumab serum concentrations [>14.6 µg/mL], tissue vedolizumab was not significantly different between responders and non-responders [0.15 vs 0.13 µg/mg; p = 0.92]. Serum sMAdCAM-1 concentrations, but not serum sICAM-1 or sVCAM-1 concentrations, were significantly higher in responders than in non-responders with adequate vedolizumab serum concentrations [1.04 vs 0.83 ng/mL, p = 0.03].Conclusions: Vedolizumab concentrations in colonic mucosal tissue of UC patients reflect the concentration in serum regardless of the macroscopic inflammatory state of the tissue. Our data show that insufficient tissue exposure does not explain non-response in UC patients with adequate serum vedolizumab concentrations.
- 27 November 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (6) , 988-993
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations
Background and Aims: Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.Methods: A paired serum sample and colonic mucosal biopsy was collected from 40 UC patients [20 endoscopic responders, 20 non-responders] at week 14 of vedolizumab treatment. Vedolizumab, soluble [s]-mucosal addressin cell adhesion molecule-1 [MAdCAM-1], s-vascular cell adhesion molecule-1 [VCAM-1] and s-intercellular adhesion molecule-1 [ICAM-1] were measured in serum and/or tissue. Endoscopic response was defined as Mayo endoscopic sub-score ≤1.Results: A significant positive correlation was observed between vedolizumab serum and colonic tissue concentrations [ρ = 0.84, p < 0.0001], regardless of the macroscopic inflammatory state of the tissue. Vedolizumab tissue concentrations were lower in non-responders than in responders [0.07 vs 0.11 µg/mg, p = 0.04]. In the subgroup of patients with adequate vedolizumab serum concentrations [>14.6 µg/mL], tissue vedolizumab was not significantly different between responders and non-responders [0.15 vs 0.13 µg/mg; p = 0.92]. Serum sMAdCAM-1 concentrations, but not serum sICAM-1 or sVCAM-1 concentrations, were significantly higher in responders than in non-responders with adequate vedolizumab serum concentrations [1.04 vs 0.83 ng/mL, p = 0.03].Conclusions: Vedolizumab concentrations in colonic mucosal tissue of UC patients reflect the concentration in serum regardless of the macroscopic inflammatory state of the tissue. Our data show that insufficient tissue exposure does not explain non-response in UC patients with adequate serum vedolizumab concentrations.
- Open Access
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S411-S412
P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
Multiple studies have reported the association between vedolizumab serum concentrations and endoscopic outcomes in patients with ulcerative colitis (UC). However, little is known about drug consumption in tissue and the relationship with mucosal inflammation. This study aimed to investigate vedolizumab concentrations in the tissue of UC patients and the correlation with their inflammatory state and serum levels. A paired serum sample and colonic mucosal biopsy were collected in 36 UC patients at week 14 of vedolizumab treatment. In non-responders, defined as a Mayo endoscopic subscore of ≥2, inflamed colonic biopsies were taken in the sigmoid around 20–30 cm from the anal verge. In responders, defined as a Mayo endoscopic subscore ≤ 1, a biopsy was taken in a macroscopically uninflamed area at the same location. Biopsies were lysed by the addition of 10 μl lysis buffer (50 mM Tris, 0.1% Triton X-100 and 100 mM NaCl) per mg tissue and vortexed every 5 min during 1 h. Total protein content was measured and normalised to 3 mg/ml before analysis of the vedolizumab concentration using an in-house developed ELISA. Results are expressed as µg vedolizumab/mg total protein content. A positive correlation was observed between vedolizumab concentrations in tissue and serum (Spearman r = 0.8447, p < 0.0001), both in inflamed (r = 0.8609, p n = 16) and uninflamed tissue (r = 0.7925, p n = 20). The median tissue vedolizumab concentration in patients with Mayo endoscopic subscore 0, 1, 2 and 3 were 0.120, 0.074, 0.062 and 0.064 μg/mg, respectively (p < 0.01, see figure), indicating that tissue drug levels inversely correlate with the severity of inflammation. Vedolizumab tissue concentrations were significantly lower in non-responders compared with responders (0.064 vs. 0.112 μg/mg, p p p = 0.0523). This finding suggests that if two patients have the same serum vedolizumab concentration, the patient with mucosal inflammation is more likely to have lower tissue levels than the patient with no or limited inflammation. Vedolizumab concentrations in colonic mucosal tissue of UC patients inversely correlate with the severity of inflammation. As the serum-to-tissue ratio of vedolizumab is numerically higher in non-responders compared with responders, the relative distribution of vedolizumab in serum and tissue might be more important than the drug concentration alone.
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S411-S412
Open AccessP464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
Multiple studies have reported the association between vedolizumab serum concentrations and endoscopic outcomes in patients with ulcerative colitis (UC). However, little is known about drug consumption in tissue and the relationship with mucosal inflammation. This study aimed to investigate vedolizumab concentrations in the tissue of UC patients and the correlation with their inflammatory state and serum levels. A paired serum sample and colonic mucosal biopsy were collected in 36 UC patients at week 14 of vedolizumab treatment. In non-responders, defined as a Mayo endoscopic subscore of ≥2, inflamed colonic biopsies were taken in the sigmoid around 20–30 cm from the anal verge. In responders, defined as a Mayo endoscopic subscore ≤ 1, a biopsy was taken in a macroscopically uninflamed area at the same location. Biopsies were lysed by the addition of 10 μl lysis buffer (50 mM Tris, 0.1% Triton X-100 and 100 mM NaCl) per mg tissue and vortexed every 5 min during 1 h. Total protein content was measured and normalised to 3 mg/ml before analysis of the vedolizumab concentration using an in-house developed ELISA. Results are expressed as µg vedolizumab/mg total protein content. A positive correlation was observed between vedolizumab concentrations in tissue and serum (Spearman r = 0.8447, p < 0.0001), both in inflamed (r = 0.8609, p n = 16) and uninflamed tissue (r = 0.7925, p n = 20). The median tissue vedolizumab concentration in patients with Mayo endoscopic subscore 0, 1, 2 and 3 were 0.120, 0.074, 0.062 and 0.064 μg/mg, respectively (p < 0.01, see figure), indicating that tissue drug levels inversely correlate with the severity of inflammation. Vedolizumab tissue concentrations were significantly lower in non-responders compared with responders (0.064 vs. 0.112 μg/mg, p p p = 0.0523). This finding suggests that if two patients have the same serum vedolizumab concentration, the patient with mucosal inflammation is more likely to have lower tissue levels than the patient with no or limited inflammation. Vedolizumab concentrations in colonic mucosal tissue of UC patients inversely correlate with the severity of inflammation. As the serum-to-tissue ratio of vedolizumab is numerically higher in non-responders compared with responders, the relative distribution of vedolizumab in serum and tissue might be more important than the drug concentration alone.
- 15 December 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (12) , 3339-3348
Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis
Mice deficient in IFN-γ (IFN-γ knockout [KO] mice) develop a systemic inflammatory syndrome in response to CFA, in contrast to CFA-challenged wild-type (WT) mice who only develop a mild inflammation. Symptoms in CFA-challenged IFN-γ KO resemble systemic juvenile idiopathic arthritis (sJIA), a childhood immune disorder of unknown cause. Dysregulation of innate immune cells is considered to be important in the disease pathogenesis. In this study, we used this murine model to investigate the role of NK cells in the pathogenesis of sJIA. NK cells of CFA-challenged IFN-γ KO mice displayed an aberrant balance of activating and inhibitory NK cell receptors, lower expression of cytotoxic proteins, and a defective NK cell cytotoxicity. Depletion of NK cells (via anti–IL-2Rβ and anti–Asialo-GM1 Abs) or blockade of the NK cell activating receptor NKG2D in CFA-challenged WT mice resulted in increased severity of systemic inflammation and appearance of sJIA-like symptoms. NK cells of CFA-challenged IFN-γ KO mice and from anti-NKG2D–treated mice showed defective degranulation capacities toward autologous activated immune cells, predominantly monocytes. This is in line with the increased numbers of activated inflammatory monocytes in these mice which was particularly reflected in the expression of CCR2, a chemokine receptor, and in the expression of Rae-1, a ligand for NKG2D. In conclusion, NK cells are defective in a mouse model of sJIA and impede disease development in CFA-challenged WT mice. Our findings point toward a regulatory role for NK cells in CFA-induced systemic inflammation via a NKG2D-dependent control of activated immune cells.
- 15 December 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (12) , 3339-3348
Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis
Mice deficient in IFN-γ (IFN-γ knockout [KO] mice) develop a systemic inflammatory syndrome in response to CFA, in contrast to CFA-challenged wild-type (WT) mice who only develop a mild inflammation. Symptoms in CFA-challenged IFN-γ KO resemble systemic juvenile idiopathic arthritis (sJIA), a childhood immune disorder of unknown cause. Dysregulation of innate immune cells is considered to be important in the disease pathogenesis. In this study, we used this murine model to investigate the role of NK cells in the pathogenesis of sJIA. NK cells of CFA-challenged IFN-γ KO mice displayed an aberrant balance of activating and inhibitory NK cell receptors, lower expression of cytotoxic proteins, and a defective NK cell cytotoxicity. Depletion of NK cells (via anti–IL-2Rβ and anti–Asialo-GM1 Abs) or blockade of the NK cell activating receptor NKG2D in CFA-challenged WT mice resulted in increased severity of systemic inflammation and appearance of sJIA-like symptoms. NK cells of CFA-challenged IFN-γ KO mice and from anti-NKG2D–treated mice showed defective degranulation capacities toward autologous activated immune cells, predominantly monocytes. This is in line with the increased numbers of activated inflammatory monocytes in these mice which was particularly reflected in the expression of CCR2, a chemokine receptor, and in the expression of Rae-1, a ligand for NKG2D. In conclusion, NK cells are defective in a mouse model of sJIA and impede disease development in CFA-challenged WT mice. Our findings point toward a regulatory role for NK cells in CFA-induced systemic inflammation via a NKG2D-dependent control of activated immune cells.
- Open Access
- 1 October 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (10) , 2232-2235.e1
Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy
- 1 October 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (10) , 2232-2235.e1
Open AccessDefining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy
- Open Access
- 16 August 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 106 (5) , 945-954
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Biologicals introduced a major shift in the treatment of patients suffering from inflammatory bowel diseases. Despite providing a tight disease control for many patients, a considerable proportion of patients will fail to respond favorably to treatment or will lose response over time. Therapeutic drug monitoring emerged as a valuable tool to guide clinical decision making as serum drug concentrations have been linked to outcomes. Focusing on mucosal healing as the ultimate treatment goal, different drug concentration thresholds to achieve this outcome have been identified in the literature and are summarized in this review. For therapeutic drug monitoring to be successful in guiding clinical decision making, the used assay, the sampling time point, and the outcome that is aimed for should be taken into account when interpreting drug concentration thresholds. Awareness of these essential aspects among clinicians will improve the implementation of therapeutic drug monitoring and aid in making an evidence‐based decision.
- 16 August 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 106 (5) , 945-954
Open AccessAchieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Biologicals introduced a major shift in the treatment of patients suffering from inflammatory bowel diseases. Despite providing a tight disease control for many patients, a considerable proportion of patients will fail to respond favorably to treatment or will lose response over time. Therapeutic drug monitoring emerged as a valuable tool to guide clinical decision making as serum drug concentrations have been linked to outcomes. Focusing on mucosal healing as the ultimate treatment goal, different drug concentration thresholds to achieve this outcome have been identified in the literature and are summarized in this review. For therapeutic drug monitoring to be successful in guiding clinical decision making, the used assay, the sampling time point, and the outcome that is aimed for should be taken into account when interpreting drug concentration thresholds. Awareness of these essential aspects among clinicians will improve the implementation of therapeutic drug monitoring and aid in making an evidence‐based decision.
- Open Access
- 20 April 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 390-397
Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis
Background Cost‐effective use of biologicals is becoming increasingly important. Monitoring drug concentrations has emerged as a valuable tool to guide clinical decision‐making as drug concentrations have been linked to clinical outcomes. The presence of a concentration‐response relationship for ustekinumab at trough is uncertain due to the contradictory results reported. Objectives To investigate the relationship between 4‐week post injection ustekinumab concentrations and clinical response in psoriasis patients. Methods In this cross‐sectional study, 49 moderate‐to‐severe psoriasis patients treated with 45 or 90 mg ustekinumab every 12 weeks for ≥16 weeks were included. Ustekinumab serum concentrations and anti‐ustekinumab antibodies were measured at week 4 upon injection and disease severity was assessed by Psoriasis Area and Severity Index (PASI). Results At week 4 upon injection, a significant negative correlation was observed between ustekinumab concentrations and absolute PASI score up to 5.9 μg/ml (ρ = ‐0.357, p = 0.032). Ustekinumab concentrations were higher in optimal responders (PASI≤2) compared to suboptimal responders (PASI>2) (4.0 vs 2.8 μg/ml, p = 0.036). The ustekinumab concentration threshold associated with optimal response was determined to be 3.6 μg/ml (area under the curve = 0.71, sensitivity = 86%, specificity = 63%). Only one patient (2%) had anti‐ustekinumab antibodies. Psoriatic arthritis was identified as an independent predictor of higher PASI scores and higher ustekinumab concentrations (p = 0.003 and p = 0.048, respectively). Conclusion A concentration‐response relationship at week 4 upon injection was observed for ustekinumab‐treated psoriasis patients. Monitoring 4‐week post injection ustekinumab concentrations could timely identify underexposed patients who might benefit from treatment optimization.
- 20 April 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 390-397
Open AccessClinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis
Background Cost‐effective use of biologicals is becoming increasingly important. Monitoring drug concentrations has emerged as a valuable tool to guide clinical decision‐making as drug concentrations have been linked to clinical outcomes. The presence of a concentration‐response relationship for ustekinumab at trough is uncertain due to the contradictory results reported. Objectives To investigate the relationship between 4‐week post injection ustekinumab concentrations and clinical response in psoriasis patients. Methods In this cross‐sectional study, 49 moderate‐to‐severe psoriasis patients treated with 45 or 90 mg ustekinumab every 12 weeks for ≥16 weeks were included. Ustekinumab serum concentrations and anti‐ustekinumab antibodies were measured at week 4 upon injection and disease severity was assessed by Psoriasis Area and Severity Index (PASI). Results At week 4 upon injection, a significant negative correlation was observed between ustekinumab concentrations and absolute PASI score up to 5.9 μg/ml (ρ = ‐0.357, p = 0.032). Ustekinumab concentrations were higher in optimal responders (PASI≤2) compared to suboptimal responders (PASI>2) (4.0 vs 2.8 μg/ml, p = 0.036). The ustekinumab concentration threshold associated with optimal response was determined to be 3.6 μg/ml (area under the curve = 0.71, sensitivity = 86%, specificity = 63%). Only one patient (2%) had anti‐ustekinumab antibodies. Psoriatic arthritis was identified as an independent predictor of higher PASI scores and higher ustekinumab concentrations (p = 0.003 and p = 0.048, respectively). Conclusion A concentration‐response relationship at week 4 upon injection was observed for ustekinumab‐treated psoriasis patients. Monitoring 4‐week post injection ustekinumab concentrations could timely identify underexposed patients who might benefit from treatment optimization.
- Open Access
- 8 February 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (7) , 864-872
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn’s disease [CD]. Real-life data in CD patients receiving ustekinumab intravenously [IV] during induction, followed by subcutaneous [SC] maintenance, are lacking. We assessed efficacy of ustekinumab and studied exposure-response correlations. We performed a prospective study in 86 CD patients predominantly refractory or intolerant to anti-tumour necrosis factor agents and/or vedolizumab. All received ustekinumab 6 mg/kg IV induction, with 90 mg SC every 8 weeks thereafter. Endoscopic response (50% decrease in Simple Endoscopic Score for CD [SES-CD] at Week 24), endoscopic remission [SES-CD ≤2], and clinical remission [daily stool frequency ≤2.8 and abdominal pain score ≤1] were assessed at weeks 4,8,16, and 24. Further serial analyses included patient-reported outcomes [PRO2], faecal calprotectin [fCal], and ustekinumab serum levels. SES-CD decreased from 11.5 [8.0–18.0] at baseline to 9.0 [6.0–16.0] at week [w]24 [p = 0.0009], but proportions of patients achieving endoscopic response [20.5%] or endoscopic remission [7.1%] were low. Clinical remission rates were 39.5% at w24. After IV induction, fCal dropped from baseline [1242.9 μg/g] to w4 [529.0 μg/g] and w8 [372.2 μg/g], but increased again by w16 [537.4 μg/g] and w24 [749.0 μg/g]. A clear exposure-response relationship was observed, both during induction and during maintenance therapy, with different thresholds depending on the targeted outcome. In this cohort of refractory CD patients, ustekinumab showed good clinical remission rates but limited endoscopic remission after 24 weeks. Our data suggest that higher doses may be required to achieve better endoscopic outcomes.
- 8 February 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (7) , 864-872
Open AccessUstekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn’s disease [CD]. Real-life data in CD patients receiving ustekinumab intravenously [IV] during induction, followed by subcutaneous [SC] maintenance, are lacking. We assessed efficacy of ustekinumab and studied exposure-response correlations. We performed a prospective study in 86 CD patients predominantly refractory or intolerant to anti-tumour necrosis factor agents and/or vedolizumab. All received ustekinumab 6 mg/kg IV induction, with 90 mg SC every 8 weeks thereafter. Endoscopic response (50% decrease in Simple Endoscopic Score for CD [SES-CD] at Week 24), endoscopic remission [SES-CD ≤2], and clinical remission [daily stool frequency ≤2.8 and abdominal pain score ≤1] were assessed at weeks 4,8,16, and 24. Further serial analyses included patient-reported outcomes [PRO2], faecal calprotectin [fCal], and ustekinumab serum levels. SES-CD decreased from 11.5 [8.0–18.0] at baseline to 9.0 [6.0–16.0] at week [w]24 [p = 0.0009], but proportions of patients achieving endoscopic response [20.5%] or endoscopic remission [7.1%] were low. Clinical remission rates were 39.5% at w24. After IV induction, fCal dropped from baseline [1242.9 μg/g] to w4 [529.0 μg/g] and w8 [372.2 μg/g], but increased again by w16 [537.4 μg/g] and w24 [749.0 μg/g]. A clear exposure-response relationship was observed, both during induction and during maintenance therapy, with different thresholds depending on the targeted outcome. In this cohort of refractory CD patients, ustekinumab showed good clinical remission rates but limited endoscopic remission after 24 weeks. Our data suggest that higher doses may be required to achieve better endoscopic outcomes.
- 27 December 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (7) , 1175-1181
Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients
Background and Aim: The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti‐vedolizumab antibodies (AVA) are frequently underestimated because most assays are not drug‐tolerant and unable to detect antidrug antibodies while there is drug in the circulation. This study aimed to explore which antidrug antibody assay is best suited to detect AVA and investigated immunogenicity of vedolizumab in inflammatory bowel disease (IBD) patients discontinuing vedolizumab therapy.Methods: A drug‐tolerant affinity capture elution (ACE) assay was developed for the measurement of AVA in the presence of vedolizumab and compared with the previously established drug‐resistant and drug‐sensitive assays. Vedolizumab and AVA were measured at week 6, at the last infusion, and 12–20 weeks after treatment discontinuation in a cohort of 40 vedolizumab‐treated IBD patients who stopped treatment due to primary non‐response, loss of response, or adverse events.Results: The drug‐tolerant ACE assay could detect AVA in samples that the drug‐resistant and drug‐sensitive assays were unable to. Using the drug‐tolerant ACE assay, 3 (8%) out of 40 vedolizumab‐treated IBD patients who discontinued therapy were AVA positive at week 6, whereas no AVA were detected at the last infusion nor after treatment discontinuation. Primary non‐responders had numerically lower median vedolizumab concentrations at week 6 compared with patients with loss of response (20.3 vs 30.7 μg/mL, respectively, P = 0.0570).Conclusions: Immunogenicity of vedolizumab is not the driving force of treatment failure, and AVA do not increase upon treatment discontinuation in vedolizumab‐treated IBD patients. Underexposure during induction might partially be responsible for primary non‐response.
- 27 December 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (7) , 1175-1181
Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients
Background and Aim: The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti‐vedolizumab antibodies (AVA) are frequently underestimated because most assays are not drug‐tolerant and unable to detect antidrug antibodies while there is drug in the circulation. This study aimed to explore which antidrug antibody assay is best suited to detect AVA and investigated immunogenicity of vedolizumab in inflammatory bowel disease (IBD) patients discontinuing vedolizumab therapy.Methods: A drug‐tolerant affinity capture elution (ACE) assay was developed for the measurement of AVA in the presence of vedolizumab and compared with the previously established drug‐resistant and drug‐sensitive assays. Vedolizumab and AVA were measured at week 6, at the last infusion, and 12–20 weeks after treatment discontinuation in a cohort of 40 vedolizumab‐treated IBD patients who stopped treatment due to primary non‐response, loss of response, or adverse events.Results: The drug‐tolerant ACE assay could detect AVA in samples that the drug‐resistant and drug‐sensitive assays were unable to. Using the drug‐tolerant ACE assay, 3 (8%) out of 40 vedolizumab‐treated IBD patients who discontinued therapy were AVA positive at week 6, whereas no AVA were detected at the last infusion nor after treatment discontinuation. Primary non‐responders had numerically lower median vedolizumab concentrations at week 6 compared with patients with loss of response (20.3 vs 30.7 μg/mL, respectively, P = 0.0570).Conclusions: Immunogenicity of vedolizumab is not the driving force of treatment failure, and AVA do not increase upon treatment discontinuation in vedolizumab‐treated IBD patients. Underexposure during induction might partially be responsible for primary non‐response.